???global.info.a_carregar???
Ana Filipa Santos André. Concluiu o(a) Mestrado em Biologia Molecular e Genética em 2016 pelo(a) Universidade de Lisboa Faculdade de Ciências e Licenciatura em Ciências Biomédicas em 2014 pelo(a) Universidade do Algarve. É Estudante no(a) Universidade de Lisboa Faculdade de Medicina Veterinária. Publicou 3 artigos em revistas especializadas. Nas suas atividades profissionais interagiu com 15 colaborador(es) em coautorias de trabalhos científicos.
Identification

Personal identification

Full name
Ana Filipa Santos André

Citation names

  • S. André, Ana
  • Andre, Ana

Author identifiers

Ciência ID
511C-998F-DAAD
ORCID iD
0000-0002-1916-6401

Languages

Language Speaking Reading Writing Listening Peer-review
Portuguese Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
English Beginner (A1) Intermediate (B1) Intermediate (B1) Intermediate (B1)
Education
Degree Classification
2018/01 - 2021
Ongoing
 Doutoramento em Ciências Veterinárias (Doutoramento)
Major in Especialização em Ciências Biológicas e Biomédicas
Universidade de Lisboa Faculdade de Medicina Veterinária, Portugal
"Development of novel antibody-drug conjugated molecules for treatment of B-cell malignancies" (THESIS/DISSERTATION)
2016
Concluded
 Biologia Molecular e Genética (Mestrado)
Universidade de Lisboa Faculdade de Ciências, Portugal
"Selection of single domain antibodies against the CD20 receptor: A new treatment with potential anti-tumor properties for B-cell malignancies" (THESIS/DISSERTATION)
 17
2014
Concluded
 Ciências Biomédicas (Licenciatura)
Universidade do Algarve, Portugal
"Estudo do efeito putativo de um polimorfismo identificado no promotor do gene da OPTN na predisposição para a Doença Óssea de Paget " (THESIS/DISSERTATION)
 15
Affiliation

Others

Category
Host institution 		Employer
2018/01/02 - Current Estudante Universidade de Lisboa Faculdade de Medicina Veterinária, Portugal
2016/12/02 - 2017/12/31 Bolsa de Investigação para Mestre no âmbito do projeto: "Overcoming the Brain Drug Delivery Bottleneck: Development of single domain antibodies for brain targeting and drug delivery across the Blood B Universidade de Lisboa Faculdade de Medicina Veterinária, Portugal
2016/07/11 - 2016/07/15 Workshop on Fluorescence and High-Throughput Microscopy Universidade de Lisboa Faculdade de Ciências, Portugal
2016/04/04 - 2016/04/15 Curso de Experimentação Animal, nível C Universidade de Lisboa Faculdade de Medicina Veterinária, Portugal
Outputs

Publications

Book chapter
  1. Aires-da-Silva, F.; Dias, J.; Aguiar, S. I.; Marques, F.; André, A.; Gil, S.; Tavares, L.. "Novel Diagnostic and Therapeutic Immunologic Strategies to Overcome Infectious, Oncologic and Neurodegenerative Disorders". In Advances in Animal Health, Medicine and Production, 436-459. Springer International Publishing, 2020.
    10.1007/978-3-030-61981-7_24
Conference poster
  1. S. André, Ana. "Single-domain antibodies and canine lymphoma model as a promising approach to develop potent antibody-drug conjugated compounds". Paper presented in Antibody Engineering & Therapeutics, San Diego, 2019.
  2. S. André, Ana. "In vivo Phage Display Selection for Development of Highly Specific Antibody Drug Conjugates for Non-Hodgkin's Lymphoma". Paper presented in PEGS Europe, 2019.
  3. S. André, Ana. "A novel functional strategy for the development of highly specific antibody drug conjugates for non-Hodgkin’s lymphoma.". Paper presented in CIISA Congress 2018, 2018.
  4. S. André, Ana. "A novel functional strategy for the development of highly specific antibody drug conjugates for non-Hodgkin’s lymphoma.". Paper presented in PEGS Europe, 2018.
  5. S. André, Ana. "Single domain antibodies for brain targeting and drug delivery". Paper presented in Microbiotec'17, Porto, Portugal, 2017.
  6. S. André, Ana. "In vitro and in vivo antitumor properties of histone deacetylase inhibitors in canine diffuse large B-cell lymphoma". Paper presented in Microbiotec'17, Porto, Portugal, 2017.
  7. Limpaiboon, Temduang; Sriraksa, Ruethairat. "Histone Deacetylase Inhibitors - A novel therapy for canine lymphoma". Paper presented in XIII Congresso do Hospital Veterinário Montenegro, Europarque, Santa Maria da Feira, 2017.
  8. S. André, Ana. "Clinical and Immunological characterization of naturally occuring canine lymphoma". Paper presented in XIII Congresso do Hospital Veterinário Montenegro, Europarque, Santa Maria da Feira, 2017.
  9. S. André, Ana. "Single-domain antibodies for brain targeting and drug delivery". Paper presented in Antibody Engineering & Therapeutics 2016: The antibody society’s annual meeting, San Diego, CA, 2016.
Journal article
  1. S. André, Ana. "Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates**". Angewandte Chemie International Edition (2021): http://dx.doi.org/10.1002/anie.202109835.
    10.1002/anie.202109835
  2. Sandra Isabel Aguiar; Joana N. R. Dias; Ana André; Marta Lisete Silva; Diana Martins; Belmira Carrapiço; Miguel Castanho; et al. "Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening". Pharmaceutics (2021): https://www.mdpi.com/1999-4923/13/10/1598.
    10.3390/pharmaceutics13101598
  3. S. André, Ana. "Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma.". Frontiers in veterinary science (2021): https://europepmc.org/articles/PMC8427286.
    10.3389/fvets.2021.621758
  4. André, Ana. "Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies.". PloS one (2018): http://europepmc.org/articles/PMC6310248.
    10.1371/journal.pone.0208147
  5. André, Ana. "The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.". Oncotarget (2018): http://europepmc.org/articles/PMC6033347.
    10.18632/oncotarget.25580
  6. Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; et al. "Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.". (2017): http://europepmc.org/abstract/med/28549690.
    10.1016/j.jbiotec.2017.05.017
Distinctions

Award

2021 Melhor trabalho de Doutoramento na área de investigação fundamental
Universidade de Lisboa, Portugal

redeSAUDE, Portugal